Growth hormone treatment downregulates serum leptin levels in children independent of changes in body mass index.
The changes in serum leptin levels during growth hormone (GH) treatment were studied in 27 children, 17 with GH deficiency (GHD), 10 with idiopathic short stature (ISS), and 9 with Prader-Willi syndrome (PWS). Within 1 month of GH treatment, serum leptin levels decreased by 40% in the GHD children (p < 0.01). There was no significant change in serum leptin level in the children with ISS. In children with PWS, the mean serum leptin level decreased by almost 60% after 3 months of treatment (p < 0.001). Thereafter, no further decline was observed in any of the 3 groups. Changes in body composition became evident first after the 3 months of treatment. In the GHD children, the BMI was unchanged while the mean body fat percentage was 2.7% lower after 1 year of GH treatment (p < 0.05). In the ISS children, neither BMI nor body fat percentage were significantly changed during treatment. The PWS children exhibited a significant decrease in BMI after 6 months of GH treatment without any further change during the remaining period of treatment. In this group, the mean body fat percentage decreased from 42 +/- 2.4 to 28 +/- 2.2% after treatment (p < 0.001). The finding that the fall in leptin occurs before changes in body composition become detectable suggests a direct effect of GH on leptin production, metabolism, or clearance.
Elimam
A
A
Department of Pediatrics, Endocrine Research Unit, Huddinge Hospital, Huddinge, Sweden.
Lindgren
A C
AC
Norgren
S
S
Kamel
A
A
Skwirut
C
C
Bang
P
P
Marcus
C
C
D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D002648:Child; D002675:Child, Preschool; D015536:Down-Regulation / Q000187:drug effects; D013006:Growth Hormone / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D020738:Leptin / Q000097:blood*; D011218:Prader-Willi Syndrome / Q000097:blood* / Q000188:drug therapy
D020738:Leptin; D013006:Growth Hormone